切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2018, Vol. 08 ›› Issue (04) : 163 -165. doi: 10.3877/cma.j.issn.2095-2015.2018.04.005

所属专题: 文献

综述

非酒精性脂肪性肝病与肠道菌群的关系
王冰心1, 白珊珊1, 张佳佳1, 党小红2,()   
  1. 1. 030000 太原,山西医科大学在读硕士研究生
    2. 030000 太原,山西医科大学第一医院消化内科
  • 收稿日期:2018-04-12 出版日期:2018-08-01
  • 通信作者: 党小红

Relationship between non-alcoholic fatty liver disease and intestinal flora

Bingxin Wang1, Shanshan Bai1, Jiajia Zhang1, Xiaohong Dang2,()   

  1. 1. Postgraduate Student, Shanxi Medical University
    2. Department of Gastroenterology, First Hospital of Shanxi Medical University, Taiyuan 030000, China
  • Received:2018-04-12 Published:2018-08-01
  • Corresponding author: Xiaohong Dang
  • About author:
    Corresponding author: Dang Xiaohong, Email:
引用本文:

王冰心, 白珊珊, 张佳佳, 党小红. 非酒精性脂肪性肝病与肠道菌群的关系[J]. 中华消化病与影像杂志(电子版), 2018, 08(04): 163-165.

Bingxin Wang, Shanshan Bai, Jiajia Zhang, Xiaohong Dang. Relationship between non-alcoholic fatty liver disease and intestinal flora[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(04): 163-165.

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是一种多病因导致的临床病理综合征,已成为最常见的慢性肝病之一,目前NAFLD完整的生理机制尚不完全清楚,近年来提出肠道菌群通过调控能量代谢、增加内源性乙醇、调节胆汁酸及胆碱代谢,破坏免疫平衡引发机体低度炎症等途径促进NAFLD的发生、发展,本文就肠道菌群与NAFLD的相关机制做一概述。

Non-alcoholic fatty liver disease(NAFLD)is a clinical pathological syndrome caused by multiple etiologies.It has become one of the most common chronic liver diseases.The complete physiological mechanism of NAFLD is not fully understood.The recent researches suggest that intestinal flora can promote the occurrence and development of NAFLD by regulating the energy metabolism, increasing the endogenous ethanol, adjusting metabolism of bile acid and choline, damaging the immune balance and triggering the low-grade inflammation.This paper summarizes the mechanism of intestinal flora and NAFLD.

14
Aron-Wisnewsky J, Gaborit B, Dutour A, et al.Gut microbiota and non-alcoholic fatty liver disease: new insights[J]. Clin Microbiol Infect, 2013, 19(4): 338-348.
15
Zhu LX, Baker SS, Gill C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients: a connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57(2): 601-609.
16
申瑞玲,林娟.肠道菌群与Ⅱ型糖尿病作用机制综述[J].粮食与油脂, 2014, 27(9): 5-8.
17
Spencer MD, Hamp TJ, Reid RW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J]. Gastroenterology, 2011, 140(3): 976-986.
18
欧强,杨华,赵亚娟,吴晓林.蛋氨酸-胆碱缺乏饮食诱导的大、小鼠非酒精性脂肪性肝病模型的特点及差异[J].肝脏, 2017, 22(10): 933-937.
19
Sherriff JL, O′Sullivan TA, et al.Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes[J]. Adv Nutr, 2016, 7(1): 5-13.
20
张久聪,聂青和.胆汁酸代谢及相关进展[J].胃肠病学和肝病学杂志, 2008(11): 953-956.
21
McMahan R, Wang XX, Cheng LL, et al.Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J]. J Biol Chem, 2013, 288(7): 11761-11770.
22
Schubert K, Olde Damink Steven WM, von BM, et al.Interactions between bile salts, gut microbiota, and hepatic innate immunity[J]. Immunol Rev, 2017, 279(1): 23-35.
23
Takeuchi O, Akira SZ.Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820.
24
Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(23): 7381-7391.
25
殷小磊,卢伟娜,冯丽英.LPS/TLR4信号途径在非酒精性脂肪性肝病中的作用[J].世界华人消化杂志, 2013, 21(28): 2957-2962.
26
Cani PD, Amar J, Iglesias MA, et al.Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56(7): 1761-1772.
27
Miura K, Kodama Y, Inokuchi S, et al.Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice[J]. Gastroenterology, 2010, 139(1): 323-334.e7.
28
Pekkala S, Munukka E, Kong LJ, et al.Toll-like receptor 5 in obesity: the role of gut microbiota and adipose tissue inflammation[J]. Obesity(Silver Spring), 2015, 23(3): 581-590.
1
Buzzetti E, Pinzani M, Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048.
2
Zezos P, Renner EL.Liver transplantation and non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(42): 15532-15538.
3
Bedossa P. Pathology of non-alcoholic fatty liver disease[J]. Liver Int, 2017, 37(suppl 1): 85-89.
4
Roberfroid M, Gibson GR, Hoyles L, et al.Prebiotic effects: Metabolic and health benefits[J]. Br J Nutr, 2010, 104(suppl 2): s1-s63.
5
Robles AV, Guarner F. Linking the gut microbiota to human health[J]. Br J Nutr, 2013, 109, (suppl 2): S21-S26.
6
Le CE, Nielsen T, Qin JJ.Richness of human gut microbiome correlates with metabolic markers[J]. Nature, 2013, 500(7464): 541-546.
7
刘慧,朱文娅,孙涛.非酒精性脂肪性肝病肠道菌群变化及其与胰岛素抵抗的关系[J].中国临床医生, 2014, 42(5): 31-33.
8
丁佳,吴健.肠-肝轴与非酒精性脂肪性肝病[J].微生物与感染, 2014, 9(2): 65-70.
9
王峻瑶,刘玉兰.肠-肝轴在非酒精性脂肪性肝病发生和发展中的作用[J].实用肝脏病杂志, 2012, 15(4): 276-278.
10
Wieland A, Frank DN, Harnke B, et al.Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2015, 42(9): 1051-1063.
11
Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease[J]. Children(Basel), 2017, 4(8). pii: E66.
12
Bäckhed F, Ding H, Wang T, et al.The gut microbiota as an environmental factor that regulates fat storage[J]. Proc Natl Acad Sci U S A, 2004, 101(44): 15718-15723.
13
Samuel BS, Shaito A, Motoike T, et al.Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41[J]. Proc Natl Acad Sci U S A, 2008, 105(43): 16767-16772.?
29
Wree A, McGeough MD, Inzaugarat ME, et al.NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF[J]. Hepatology, 2017.
30
Levy M, Shapiro H, Thaiss CA, et al.NLRP6: A Multifaceted Innate Immune Sensor[J]. Trends Immunol, 2017, 38(4): 248-260.
[1] 李晓晖, 上官昌盛, 向英, 裴芝皆, 车俊志, 谢飞. 3D腹腔镜袖状胃切除术后机体能量代谢与多囊卵巢综合征患者性激素水平关系[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 538-541.
[2] 李丹阳, 李满祥. 肠道菌群失调在肺动脉高压发病中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 432-434.
[3] 何吉鑫, 杨燕妮, 王继伟, 李建国, 谢铭. 肠道菌群及肠道代谢产物参与慢性便秘发生机制的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 495-499.
[4] 乔小梅, 孔凯丽, 方敬爱, 张晓东. "肠-皮肤轴"与尿毒症皮肤病变的关系研究进展[J]. 中华肾病研究电子杂志, 2023, 12(05): 291-294.
[5] 李娜, 朱国贞. 肠道菌群及其代谢产物在急性肾损伤中的作用研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 215-219.
[6] 王宁, 刘彦哲, 吴紫莺, 曾超, 雷光华, 沙婷婷, 王伊伦. 基于孟德尔随机化研究探讨肠道菌群与肌少症表型的因果关联[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 333-342.
[7] 屈霄, 王靓, 陆萍, 何斌, 孙敏. 外周血炎症因子及肠道菌群特征与活动性溃疡性结肠炎患者病情的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 466-470.
[8] 孙晗, 武侠. 成人肠易激综合征患者肠道菌群特征与不同分型患者生活质量和精神症状的相关性[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 461-465.
[9] 廖想, 李爽, 曾瑶. 2012-2021年粪菌移植研究的趋势及热点分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 93-99.
[10] 张大涯, 陈世锔, 陈润祥, 张晓冬, 李达, 白飞虎. 肠道微生物群对代谢相关脂肪性肝病发展的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 828-833.
[11] 韩家超, 王飞飞, 柳子宁, 胡冀陶, 孟泽松, 雒月云, 王贵英. 二甲双胍的作用机制研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(03): 349-355.
[12] 杜青瑶, 曹颖雯, 林健雄, 郝润, 王静敏, 徐锐权, 寇晓霞. 肠道菌群促进诺如病毒感染的机制[J]. 中华临床实验室管理电子杂志, 2023, 11(04): 241-244,255.
[13] 于乾雪, 廖学梅, 孙龙龙, 范梦莹, 蒋明超, 孟慧, 李瑞基. 线粒体功能障碍与卵巢早衰的研究进展[J]. 中华诊断学电子杂志, 2023, 11(04): 283-288.
[14] 刘艳, 唐神结. 肠道菌群与抗结核药及其所致肝损伤的相关性研究进展[J]. 中华诊断学电子杂志, 2023, 11(02): 82-86.
[15] 金泽平, 董晶, 柳云鹏, 汪阳. 菌群-肠道-脑轴与缺血性卒中危险因素关系的研究进展[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 510-517.
阅读次数
全文


摘要